Bruce Levine

Dr. Bruce Levine currently serves as the Barbara and Edward Netter Professor in Cancer Gene Therapy and is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania. Dr. Levine has led several first-in-human clinical trials employing adoptive immunotherapy, including the first use of a lentiviral vector, the first infusions of gene-edited cells, and the first use of lentivirally modified cells to treat cancer. Dr. Levine is co-inventor on 30 issued U.S. patents, including the first FDA-approved gene therapy (Kymriah), a chimeric antigen receptor T cells medication for the treatment of leukemia and lymphoma, licensed to Novartis. He is a Co-Founder of Tmunity Therapeutics and Capstan Therapeutics, both which are spinouts from the University of Pennsylvania.

Dr. Levine serves as Immediate Past-President of the International Society for Cell and Gene Therapy and is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, and the National Marrow Donor Program/Be The Match ONE Forum 2020 Dennis Confer Innovate Award. Dr. Levine has authored >200 manuscripts and book chapters and has a Google Scholar citation h-index of 100. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets. Dr. Levine received a BA in Biology from the University of Pennsylvania and a PhD in Immunology and Infectious Diseases from Johns Hopkins University.